Author(s):
Mark Anderson
In Part I, we described the overall approach under the category of AugI, and then focused on recent successes in treating cancer. In Part II, we will shift to related work, still under AugI, in treating autoimmune diseases - a class that has essentially been considered incurable, at least until now.